A 48-week study of fat molecular alterations in HIV naïve patients starting tenofovir/emtricitabine with lopinavir/ritonavir or efavirenz : Greater deleterious effects of efavirenz by Gutiérrez Macià, Mª Del Mar et al.
Departament de Medicina 
Universitat Autònoma de Barcelona 
 
 
Autor:  Mª Del Mar Gutiérrez Macia 
 
Títol:   A 48-week study of fat molecular alterations in HIV naïve patients 
starting tenofovir/emtricitabine with lopinavir/ritonavir or efavirenz: 
Greater deleterious effects of efavirenz. 
 
Direcció:  Dr. Pere Domingo Pedrol. Unitat de Malalties Infeccioses. Hospital de 
la Santa Creu i Sant Pau. Universitat Autònoma de Barcelona. 
 
 
Treball de Recerca, any 2013, convocatòria de setembre 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
1
 
Index 
 
Abstract 
Introduction 
Patient and Methods 
Subjects 
Body composition measurements 
Definition of lipoatrophy, lipohypertrophy, and metabolic syndrome 
Biochemistry laboratory measurements 
Fat tissue samples 
Genes profiled in subcutaneous fat 
Statistical analyses 
Results 
 Population studied 
 Viro-immunological status 
 Metabolic changes over time 
 Body composition changes over time 
Mitochondrial DNA and gene expression in SAT over time 
Discussion 
Conclusion 
Tables and figures 
References 
 
 
 
 
  
 
2
Abstract 
Background: Conflicting reports on the effects of efavirenz (EFV) and lopinavir/ritonavir 
(LPV/r) on subcutaneous adipose tissue (SAT) have been described. 
Objective: To assess the 48-week molecular and clinical effects of LPV/r and EFV, both 
combined with tenofovir/emtricitabine (TDF/FTC), on SAT of HIV-infected, antiretroviral-
naïve patients. 
Methods: Forty-four adult HIV-infected were started LPV/r or EFV combined with 
TDF/FTC. Fasting metabolic tests, HIV RNA, CD4 cell count, and whole body and 
segmental fat measured by dual X-ray absorptiometry scans were obtained at study entry 
and at week 48. Mitochondrial DNA (mtDNA) and transcripts for mitochondrially-related 
genes, and genes involved in inflammation, adipocyte differentiation and metabolism were 
assessed in paired SAT biopsies. 
Results: Total, HDL, LDL, VLDL cholesterol and triglycerides increased significantly in the 
LPV/r and total and LDL cholesterol in the EFV group. Whole body fat and limb fat mass 
increased significantly in the LPV/r but not in the EFV group. MtDNA and cytochrome 
oxidase subunit II (COII) did not change and cytpchrome b increased significantly in EFV 
patients. Tumor necrosis factor-α (TNF-α) and monocyte chemotactic protein-1 (MCP-1) 
gene expression did not change in the LPV/r group, but significantly increased in the EFV 
group. Interleukin 18 (IL-18) decreased in LPV/r group while it increased in EFV group. 
Conclusion: Starting antiretroviral therapy with a LPV/r or EFV-based regime was 
associated with a significant increase in limb fat mass in the LPV/r group. EFV exposure 
was associated with an increased expression of genes encoding for inflammatory 
cytokines in SAT. 
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Introduction 
Antiretroviral drug toxicity is still casting a shadow over the doubtless efficacy of 
highly active antiretroviral therapy (HAART), although its overall prevalence seems to have 
decreased in recent times [1]. Among antiretroviral drug-associated toxicity, that causing 
body fat redistribution, the so-called HIV/HAART-associated lipodystrophy syndrome 
(HALS), is one of the most feared by both patients and caregivers [2]. HALS is feared 
because of the devastating consequences in terms of self-image and psychological health, 
and because there is no intervention to successfully reverse this complication [2]. 
Therefore, much effort should be made to prevent its appearance. The best preventive 
measures which can be offered to patients to prevent HALS include early start of HAART, 
and above all starting with drugs with a benign fat profile [2].  
Antiretroviral drugs with a known deleterious profile on adipocyte biology and 
function are the thymidine analogues and to a lesser extent didanosine, whereas non-
nucleoside reverse transcriptase inhibitors (NNRTI) have usually been considered as 
benign drugs with respect to their effects on adipose depots [3]. First-generation protease 
inhibitors (PI) such as nelfinavir and indinavir also exhibited significant fat toxicity and their 
negative effects were synergistic with those of nucleoside reverse transcriptase inhibitors 
(NRTI) [4]. On the other hand, lopinavir/ritonavir (LPV/r) and atazanavir have been linked 
in some studies mostly to increased trunk fat or even to visceral adipose tissue 
hypertrophy [5-7]. The ACTG 5142 clinical trial which compared head-to-head LPV/r and 
efavirenz (EFV) combined with different NRTI backbones changed the perception of the 
neutral effects of EFV on fat. In that trial, EFV-based regimes were found associated with a 
higher risk of lipoatrophy, defined as a limb fat loss > 20% from the baseline, across all 
NRTI groups compared with LPV/r [8]. 
This intriguing finding prompted us to perform a molecular and clinical study to 
assess the effects of LPV/r and EFV, both combined with tenofovir/emtricitabine 
(TDF/FTC) on gene markers of adipocyte biology and function in SAT, in HIV-infected, 
antiretroviral naïve patients, who started their first HAART regime. Our working hypothesis 
was that molecular markers of adipocyte biology and function would improve in both arms. 
 
Patients and Methods 
Subjects 
Patients were selected from the same HIV-1 infection clinic cohort, with the 
baseline visit between July 2008 and January 2010, at the Hospital de la Santa Creu i Sant 
Pau, which serves a population of 1708 HIV-1-infected patients on active follow-up. 
Inclusion criteria were having an established diagnosis of HIV-1 infection, antiretroviral-
naïve who started antiretroviral therapy with TDF/FTC combined fixed dose formulation 
plus LPV/r or with TDF/FTC/EFV compact pill. The primary endpoint of the study was the 
change in limb fat mass measured by dual energy X-ray absorptiometry (DEXA) scan from 
baseline to 48 weeks. Secondary endpoints were changes in molecular markers of 
adipocyte biology and function at SAT level.  
 At the time of study entry no patient used any other drug known to influence 
glucose or lipid metabolism or fat distribution, such as anabolic hormones or systemic 
corticosteroids, recombinant human growth hormone, or appetite stimulants. Additional 
exclusion criteria included: fasting glucose > 6.1 mmol/l, daily alcohol intake ≥ 40 g/daily, 
hypothyroidism, serum creatinine > 150 mmol/l and alanine aminotransferase o aspartate 
aminotransferase > 5 x upper limit of normal, anemia, > 10% loss in body weight in the 
preceding 6 months, and any active AIDS-defining disease. The patients were instructed 
  
 
4
not to modify diet, exercise or other habits during the study. The diagnosis of AIDS was 
based on the 1993 revised case definition of the Centers for Disease Control and 
Prevention CDC [9].  
All patients provided written informed consent before enrollment. The study was approved 
by the Ethics Committee of the Hospital de la Santa Creu i Sant Pau and complied with the 
provisions of the Good Clinical Practice guidelines and the Declaration of Helsinki. 
Baseline and follow-up measurements and treatments were done according to standard 
clinical practice at the HIV infection clinic. At study entry each patient had HIV infection 
history and demographic data recorded and anthropometric, blood pressure, viro-
immunological, and metabolic parameters measured. These measurements were repeated 
every 3 months. DEXA scans and abdominal SAT biopsies were performed at baseline 
and at week 48. Gene expression in SAT was assessed with baseline and 48-week 
samples. 
Body composition measurements 
Subjects were weighed on calibrated scales after removing shoes, outdoor clothing, 
and other heavy items. Body mass index (BMI) was calculated by dividing the weight in 
kilograms by the square of the height in meters. Waist circumference was measured to the 
nearest millimeter using anatomical landmarks as defined for the Third National Health and 
Nutrition Evaluation Survey [10]. 
Whole body DEXA scans (Hologic QDR-4500A Hologic, Inc, 590 Lincoln St, 
Waltham, MA 02154, USA) were conducted by a single operator on all the patients. The 
operator was blinded to antiretroviral treatment. The percentage of fat at the arms, legs 
and central abdomen (calculated from the mass of fat versus lean and bone mass), as well 
as total lean body mass in kilograms, was recorded. To assess fat symmetry distribution, 
the following fat ratios were analyzed: trunk/limb fat ratio by dividing trunk fat by 
appendicular fat [11], fat mass ratio by dividing the percentage of trunk fat by the 
percentage of lower limb fat [12], fat mass index by dividing whole body fat by squared 
height [13], and leg fat percentage normalized to BMI by dividing the percentage of leg fat 
mass by BMI [14]. 
Definition of lipoatrophy, lipohypertrophy, and metabolic syndrome 
Lipoatrophy was defined as a decrease in limb fat > 20% with respect to baseline, 
whereas lipohypertrophy was defined as an increase in trunk fat > 20% with respect to 
baseline value [8, 15]. The metabolic syndrome was defined according to the U.S. National 
Cholesterol Education Program (NCEP) Adult Treatment Panel III Guidelines [16] and 
modified as recommended in the latest American Heart Association/National Heart, Lung, 
and Blood Institute Scientific Statement [17]. 
Biochemistry laboratory measurements 
All laboratory investigations were performed after a 12 h overnight fast and at least 
5 minutes after seating prior to phlebotomy to avoid hemoconcentration, as previously 
described [16]. Insulin resistance was estimated by the homeostasis model assessment 
method (HOMA-R) as the product of the fasting concentrations of plasma insulin 
(µunits/ml) and plasma glucose (mmol/l) divided by 22.5 [18]. 
Fat tissue samples 
Fat tissue samples were obtained from SAT abdominal depot through a small 
surgical biopsy performed by an 8 mm punch under local anesthesia with mepivacaine, at 
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baseline and at week 48. One half of the SAT obtained was immediately frozen in liquid 
nitrogen and stored at -80ºC until RNA extraction.  
 
Genes profiled in subcutaneous fat 
After homogenization in RLT buffer (Qiagen, Hilden, Germany), DNA was isolated 
using standard phenol/chloroform procedures and RNA was isolated using a column-
affinity based methodology that included on-column DNA digestion (RNeasy; Qiagen). One 
microgram of RNA was transcribed into cDNA using MultiScribe reverse transcriptase and 
random-hexamer primers (TaqMan Reverse Transcription Reagents; Applied Biosystems, 
Foster City, California, CA, USA). For quantitative mRNA expression analysis, TaqMan 
reverse transcriptase (RT)-polymerase chain reaction (PCR) was performed on the ABI 
PRISM 7700HT sequence detection system (Applied Biosystems). The TaqMan RT-PCR 
reactions were performed in a final volume of 25 µl using TaqMan Universal PCR Master 
Mix, No AmpErase UNG reagent and primer pair probes specific for transcripts encoding 
the master regulators of adipogenesis peroxisome proliferator-activated receptor-γ (PPAR-
γ) (Hs00234592_m1) and CCAAT-enhancer binding protein-α (C/EBPα) 
(Hs00269972_s1), the marker genes of terminal adipogenic differentiation glucose 
transporter-4 (GLUT4)(Hs00168966_m1), and fatty acid bind protein-4 (aP2/FABP4) 
(Hs00609791_m1), the pro-inflammatory cytokines tumor necrosis factor-α (TNF-α 
Hs00174128_m1), interleukin 18 ( IL-18)(Hs99999040_m1), and monocyte chemotactic 
protein-1 (MCP-1)( Hs00234140_m1) and the marker gene for endoplasmic reticulum 
stress 78 kDa glucose-regulated protein (GPR78). The transcript levels for the mtDNA-
encoded genes cytochrome b (Cyt b) (Hs02596867_s1) and cytochrome oxidase subunit II 
(COII)( Hs02596865_g1) were determined using the same Taqman RT-PCR reactions 
method. The assessment of mtDNA levels was performed using cyt-b probe (MT-CYB) 
and referred to nuclear DNA, as determined by the amplification of the intronless gene 
CEBPα (CEBPA) [19].  Controls with no RNA, primers, or RT were included in each set of 
experiments. Each sample was run in duplicate, and the mean value of the duplicate was 
used to calculate the mRNA levels for the genes of interest. Values were normalized to 
that of the reference control (18S ribosomal RNA) using the comparative 2-∆CT method, 
following the manufacturer's instructions. Parallel calculations performed using the 
reference gene PPIA (Hs99999904_m1) yielded essentially the same results. 
Statistical analyses 
Data are expressed as frequencies and percentages or median with interquartile 
range (IQR, percentile 25 – percentile 75). HIV-1 RNA copies/ml were analysed after a 
log10 transformation. We used the Fisher’s exact test to compare categorical variables 
and the Mann-Whitney test and the Wilcoxon test for independent and dependent 
continuous data. All analyses were performed with the Statistical Package for Social 
Sciences version 17.0 (SPSS, Chicago, IL) and the level of significance for all tests was 
set at the two-sided 0.05 level. 
 
Results 
Population studied 
The study group was made up of 44 patients, 23 treated with TDF/FTC plus LPV/r 
and 21 with TDF/FTC/EFV. Demographics of patients at baseline are shown in table 1, 
where it is apparent that both groups were well balanced. The mean age of the patients 
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was 39.2 ± 10.5 years (median [IQR]: 36.5 [31.5-45.5] years). There were 36 men (81.8%) 
and 8 women (18.2%). 
Viro-immunological status 
Both groups were well balanced too with respect to virological and immunological 
parameters at baseline, including the percentage of patients with less than 200 CD4 cells 
and those with viral load ≥5 log10 copies/ml (Table 1). Seventy percent of patients had 
undetectable viral load at week 48, and among those who had it detectable the median 
viral load was 42 (IQR: 25-51) copies/ml. The median increase in CD4 cell count was > 
200 cells/mm3, and the decrease in viral load was >3.5 log10 copies/ml in both groups 
(Table 1).  
Metabolic changes over time 
Metabolic, anthropometric and fat parameters, including fat distribution symmetry 
indexes, were well balanced without statistically significant differences between groups at 
baseline (Table 2). Eight patients (18.2%) had metabolic syndrome at baseline, a 
percentage that did not increase significantly during the study period (11 patients, 25%). 
Over the 48 weeks of study, total cholesterol, HDL cholesterol, LDL cholesterol, VLDL 
cholesterol, and triglycerides increased significantly in patients exposed to LPV/r, whereas 
in the EFV arm only total cholesterol and LDL cholesterol had significant increases (Table 
3). Despite these changes, there were not significant differences in total cholesterol/HDL 
ratio between groups either at baseline or at week 48. With respect to glucose 
homeostasis, there were not significant changes over time in fasting glucose, fasting 
insulin and HOMA, except for fasting glucose in the EFV group (Table 3). There were not 
statistically significant differences in metabolic parameters between groups at week 48, 
except for a higher triglycerides in the LPV/r group and higher fasting glucose in the EFV 
group (Table 3). No patient was taking lipid-lowering drugs at baseline, whereas 5 (12.7%) 
in the LPV/r and one (4.7%) in the EFV arm were taking them at week 48 (P = 0.2304). 
Body composition changes over time 
Whole body fat, lower limb fat and limb fat mass increased significantly from 
baseline in the LPV/r group, whereas a non-significant increase was observed in the same 
parameters in the EFV one (Table 4). The mean increase in limb fat mass at week 48 was 
994 ± 732 grams in the LPV/r and 1181 ± 628 grams in the EFV group, respectively (P = 
0.9832). Two (9.5%) patients in the LPV/r and 2 (8.7%) in the EFV group had a limb fat 
loss ≥ 20% with respect of baseline at week 48 (P = 1.0). Percentages of limb fat loss > 
10% of baseline at week 48 were 21.7% and 14.3%, respectively (P = 0.7010). Two 
patients (8.7%) in the LPV/r and none in the EFV group had an increase in trunk fat mass 
≥ 20% from baseline (P = 0. 5101). Fat distribution symmetry indexes did not change 
significantly over time (Table 4). At week 48 there were no significant differences between 
both groups in terms of fat parameters and fat distribution symmetry indexes. Bone mineral 
content (BMC) and bone mineral density (BMD) significantly decreased over the study 
period, and at week 48 BMC was significantly lower in the LPV/r with respect to EFV group 
(Table 4). 
Mitochondrial DNA and gene expression in SAT over time 
Paired fat biopsies were available for 18 patients (78.3%) in the LPV/r and 17 
patients (80.9%) in the EFV group. There were not statistically significant differences with 
the whole group between patients who had paired biopsies in each arm in terms of viro-
immunological, metabolic and fat parameters at baseline. 
Mitochondrial DNA and mitochondrially-related genes 
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Baseline mtDNA abundance and COII and Cyt b gene expression levels in LPV/r 
and EFV groups were comparable (P = 0.8819, P = 0.1372, and P = 0.1979, respectively). 
The relative abundance of mtDNA did not increase significantly, and COII did not change 
significantly in either group (Figure 1). Cyt b mRNA significantly increased in the EFV but 
not in the LPV/r group (Figure 1). At week 48, the relative abundance of mtDNA and of 
COII and Cyt b transcripts were not different between groups (P = 0.3871, P = 0.8880, and 
P = 0.8430, respectively). 
 
Adipocyte differentiation and lipid metabolism 
Overall, transcript levels for adipogenesis-related genes at baseline were not 
significantly different, with the exception of GLUT4 that was higher in the LPV/r group (P = 
0.0014). The expression of PPAR-γ and C/EBPα, the two major master regulators of 
adipogenic differentiation, did not change significantly during the study (Figure2). In 
addition, consistently with these observations, the expression of marker genes of terminal 
differentiation of adipose cells, such as GLUT4 and aP2/FABP, did not change significantly  
(Figure2). Between groups comparison at week 48 did not show differences for any of 
those transcripts (P = 0.8950, P = 0.2601, and P = 0.4678, respectively). 
Genes involved in inflammation 
MCP-1, IL-18, GPR78, and TNF-α transcript levels at baseline were comparable 
between groups (P = 0.6677, P = 0.1372, P = 0. 9736, and P = 0.9473, respectively). 
MCP-1 and TNF-α transcripts did not change significantly over 48 weeks in the LPV/r 
group, whereas they showed a significant increase in the EFV group (Figure 3). GPR78 
gene expression, an indicator of the endoplasmic reticulum stress process closely related 
to inflammation, did not change significantly in both groups (Figure 3). IL-18 transcript level 
significantly decreased in the LPV/r but increased significantly in the EFV group (Figure 3). 
Between groups comparison at week 48 did not show any difference for MCP-1, GPR78 
and TNF-α transcript levels (P = 0.2219, P = 0.5743, and 0.7917, respectively), but there 
were significant differences for IL-18 gene expression (P = 0.0050). 
 
Discussion 
This study shows that LPV/r and EFV both combined with TDF/FTC for 48 weeks, 
are associated with different changes in molecular markers of adipocyte biology and 
function. However, none of them was associated with relevant changes in the abundance 
of mtDNA. LPV/r had a neutral effect on the markers studied, whereas EFV was 
associated with an increase in Cyt b and in markers of inflammation. From a clinical point 
of view, LPV/r was associated with significant increases in subcutaneous fat without 
concomitant changes in the fat distribution symmetry indexes, whereas EFV was not 
associated with increases in subcutaneous fat or with changes in fat distribution symmetry 
indexes. From a metabolic point of view, LPV/r was associated with significant increases in 
total cholesterol, triglycerides, HDL, LDL and VLDL cholesterol, whereas in the EFV arm 
total cholesterol, LDL and VLDL cholesterol also increased significantly. However, total 
cholesterol/HDL ratio did not change significantly in either arm. 
 A number of clinical trials have examined the effect of LPV/r and EFV on fat depots; 
in two of them [8, 15], EFV was associated with a higher incidence of lipoatrophy defined 
as > 20% limb fat loss from baseline value. However, in these two studies the NRTI 
backbone in the EFV arm contained zidovudine (AZT) [15] or was composed of stavudine 
and AZT in 66% of the patients in the second one [8], which could have had a substantial 
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contribution to fat loss. Notwithstanding that, whichever NRTI backbone was used, EFV 
was associated with higher degrees of lipoatrophy than LPV/r, and this was true even 
when TDF/FTC were the NRTI used [8]. These results are at odds with fat sub-studies in 
other clinical trials which show increases in subcutaneous fat in antiretroviral-naïve 
patients who start an EFV-based regime in combination with TDF/FTC [7,20]. Moreover, 
no differences were detected in these studies regarding the percentage of patients who 
experienced fat loss either with the 10% or the 20% threshold [7, 20]. Therefore, EFV from 
a clinical point of view seems safe in terms of subcutaneous adipose tissue toxicity. In our 
study, both groups showed an increase in subcutaneous fat, although this increase only 
reached statistical significance for patients in the LPV/r arm. In addition, fat distribution 
symmetry indexes remained unchanged throughout the study which suggests that the fat 
gained was symmetrically distributed. As expected, bone mineral content and density 
significantly decreased during the study, and this decrease was more pronounced in the 
LPV/r arm. It is well known that bone mineralization parameters decrease when HAART is 
started, and that this decrease is greater if TDF is part of the HAART regime and even 
greater when TDF is combined with a boosted PI [21, 22].  
 LPV/r has been associated with a range of disturbances in adipocyte biology and 
function in in vitro studies, including impairment of adipocyte differentiation [23, 24] and up-
regulation of inflammatory-related genes [23]. Moreover, LPV/r has been associated with 
adverse effects on mitochondrial function measured by an increased reactive oxygen 
species (ROS) production and has also adversely affected insulin sensitivity [24]. 
However, impairment of insulin sensitivity by LPV/r seems very dependent on the length of 
exposure [25]. These findings are at odds with our ex vivo findings of a neutral action of 
TDF/FTC plus LPV/r on SAT expression of genes related to adipocyte differentiation, 
inflammation and mitochondrial function measured by mtDNA content and expression of 
COII and Cyt b genes. EFV has been linked in in vitro studies to impairment of adipocyte 
differentiation, decreased lipogenesis, promotion of inflammation [23, 26, 27], and 
mitochondrial toxicity [28]. Moreover, in the hepatocyte model, EFV has been associated 
with profound changes in mitochondrial bioenergetics reducing cell respiration by inhibition 
of complex I of the mitochondrial respiratory chain (MRC), reducing intracellular ATP levels 
and increasing ROS production [29]. In an ex vivo study, a decrease in Cyt b and increase 
in uncoupling protein-2 (UCP-2) gene expression was found, suggesting a shift to 
anaerobic metabolism within SAT [30]. We did not find any sign of mitochondrial toxicity 
among patients exposed to EFV measured by mtDNA content whereas Cyt b gene 
expression even increased significantly during the study. This discrepancy may be 
explained by the fact that in case of toxicity mitochondrial mass may increase [31], but also 
because in one study [30] half of the patients were exposed to AZT and when Cyt b 
expression was analyzed by AZT or TDF exposure, there were significant differences 
between both arms.  
The present study did not reveal relevant changes in adipogenic genes caused by 
LPV/r- and EFV-based HAART for 48 weeks. The main difference in terms of gene 
expression at SAT level between LPV/r- and EFV-based HAART in this study was that the 
latter was associated with up-regulation of the genes encoding for inflammatory cytokines 
(i.e. TNF-α, IL-18 and MCP-1). This finding is in line with those from in vitro adipocyte 
models where EFV is associated with increases in TNF-α and MCP-1 transcript levels [23, 
27]. In these models, LPV/r was also associated with such an increase [23, 27], but to a 
lesser extent. However, this was not reproduced in our ex vivo samples for LPV/r-treated 
patients. On the other hand, protease inhibitors, including lopinavir, have been reported to 
cause endoplasmic reticulum stress in multiple tissues and cells including adipocytes [32, 
33], and this effect is known to be coupled to a pro-inflammatory induction [34]. The 
present data on unaltered GPR78, a marker of endoplasmic reticulum stress, indicate that 
this process does not appear to be involved in the preferential pro-inflammatory induction 
observed in the LPV/r-exposed SAT. The establishment of an inflammatory environment at 
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SAT and systemic level is thought to play an important part in the development of HALS 
[35]. Whether the increase in SAT inflammatory markers in the EFV arm can be linked to 
the absence of significant improvement in SAT parameters in the EFV arm, may only be a 
matter of speculation at present. 
This study has limitations; first, this is a non-randomized study and therefore no 
causal relationship must be established. Notwithstanding that, both groups were 
comparable with regard to clinical, virologic, fat, and even SAT molecular levels at 
baseline. Second, the limited number of patients and samples may have prevented us 
from finding relevant differences both in molecular and clinical parameters. Third, it has not 
explored the mitochondrial bioenergetics in samples from the patients, and this has been 
described both in vitro and ex vivo as a possible mechanism of SAT toxicity, especially by 
EFV [36]. Fourth, it has not explored the expression of genes involved in glucocorticoid 
generation which may play a role in adipocyte differentiation [30]. 
 
Conclusion 
In summary, after 48 weeks of therapy, TDF/FTC plus LPV/r significantly increased 
limb fat and lipid parameters, whereas TDF/FTC/EFV did not significantly increase limb fat 
but increased total and LDL cholesterol. The expression of genes involved in adipocyte 
differentiation and mitochondria-related genes did not change significantly in SAT from 
LPV/r-exposed patients, whereas Cyt b, and especially inflammation-related genes were 
significantly up-regulated in SAT from TDF/FTC/EFV-exposed patients.
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Tables and figures 
Table 1. Demographics, baseline and viro-immunological characteristics of the population studied 
Characteristic LPV/r 
(n = 23) 
EFV 
(n = 21) 
P value 
Age, yrs 37.0 (30.2-45.0) 36.0 (32.0-46.2) 0.8049 
Males, n (%) 18 (78.3) 18 (85.7) 0.8034 
Risk factor for HIV infection    
MsM, n (%) 12 (52.2) 14 (66.7) 0.6179 
Heterosexual, n (%) 8 34.8() 5 (23.8) 
IVDU, n (%) 3 (13.0) 2 (9.5) 
Duration of HIV infection, months 9.0 (2.0-25.7) 10.0 (2.7-34.7) 0.4651 
AIDS, n (%) 7 (30.4) 6 (28.6) 0.8923 
Smokers, n (%) 18 (78.3) 15 (71.4)  0.8617 
Alcohol consumption, g/d 20.0 (0.0-36.0) 18.0 (0.0-26.0) 0.4948 
HBV co-infection, n (%) 1 (4.3) 2 (9.5) 0.4936 
HCV co-infection, n (%) 3 (13.0) 1 (4.8) 0.6086 
Baseline CD4 cell count, cells/mm
3
 195 (45-318) 199 (108-323) 0.6982 
Baseline CD4 count, % 15 (4.0-18.7) 17 (10.5-21.2) 0.3229 
Nadir CD4 cell count < 200 cells/mm
3
, n (%) 11 (47.8) 11 (52.4) 0.7627 
Nadir CD4 cell count < 100 cells/mm
3
, n (%) 7 (30.4) 5 (23.8) 0.7403 
CD4 increase through 48 weeks, cells/mm
3
 234 (109-437) 264 (167-520) 0.5106 
Baseline CD8 cell count, cells/mm
3
 690 (355-1113) 760 (437-1017) 0.8509 
Baseline HIV-1 RNA, log10 copies/ml 5.10 (4.60-5.65) 5.47 (4.98-5.65) 0.2850 
Baseline HIV-1 RNA > 5 log10 copies/ml , n (%) 13 (56.5) 15 (71.4) 0.3596 
Undetectable HIV-1 RNA at week 48, n (%) 16 (71.4) 15 (69.6) 1.0 
Decrease HIV-1 RNA over 48 weeks, log10 
copies/ml 
-3.67 (-4.35- [-3.29]) - 4.05 (-4.8-[-3.41]) 0.3911 
Values are expressed as medians (95%CI) unless otherwise specified. TDF = tenofovir, FTC = emtricitabine, LPV/r = 
lopinavir/ritonavir, EFV = efavirenz, MsM = men who have sex with men, IVDU = intravenous drug users, HBV = Hepatitis B 
virus, HCV = Hepatitis C virus, AIDS = acquired immune deficiency syndrome  
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Table 2. Baseline anthropometric, metabolic and fat parameters 
Parameter LPV/r (n = 23) EFV (n = 21) P value 
Weight, kg 68.5 (60.0-74.9) 69.0 (62.4-74.3) 0.8971 
Height, cm 173.0 (168.2-176.7) 172.0 (166.5-180.0) 0.9906 
BMI, kg/m
2
 22.6 (20.4-24.6) 22.8 (20.9-23.9) 0.9612 
Waist circumference, cm  81.5 (77.0-87.0) 81.5 (76.0-85.0) 0.6735 
WHR 0.86 (0.83-0.92) 0.85 (0.81-0.89) 0.4049 
Systolic BP, mm Hg 110.0 (110.0-120.0) 120.0 (110.0-127.7) 0.1452 
Diastolic BP, mm Hg 70.0 (60.0-80.0) 75.0 (70.0-80.0) 0.1385 
Total cholesterol, mmol/l 4.04 (3.33-4.59) 3.86 (3.69-4.56) 0.8972 
Triglycerides, mmol/l 1.45 (0.92-2.03) 1.14 (1.01-1.40) 0.3180 
HDL cholesterol, mmol/l 0.87 (0.79-0.97) 1.02 (0.85-1.11) 0.0900 
Total cholesterol/HDL ratio 4.33 (3.50-5.49) 4.09 (3.46-4.61) 0.2621 
LDL cholesterol, mmol/l 2.29 (1.82-2.67) 1.42 (2.09-2.92) 0.3215 
VLDL cholesterol, mmol/l 0.67 (0.40-0.88) 0.54 (0.47-0.65) 0.4416 
Fasting glucose, mmol/l 4.80 (4.52-5.17) 4.80 (4.60-5.05) 0.7333 
Fasting insulin, pmol/l 28.0 (11.42-97.25) 15.2 (3.3-35.0) 0.1912 
HOMA-IR 1.77 (0.53-3.60) 0.73 (0.65-1.40) 0.5338 
Whole body fat, g 12270 (9435-17392) 15743 (9294-17613) 0.4558 
Trunk fat, g 6052 (4429-8340) 6632 (4539-9532) 0.4771 
Left leg fat, g 1932 (1315-3234) 2814 (1771-3483) 0.3229 
Lower limb fat, g 3743 (2706-6425) 5591 (3537-6864) 0.3229 
Limb fat mass, g 5056 (3472-8152) 7077 (4284-9050) 0.3062 
Trunk/limb fat ratio 1.13 (0.99-1.26) 1.05 (0.83-1.18) 0.2596 
Fat mass ratio 1.49 (1.29-1.75) 1.34 (1.07-1.59) 0.2641 
Leg fat percentage normalized to BMI 0.79 (0.73-0.96) 1.14 (0.85-1.31) 0.1037 
Fat mass index, kg/m
2
 4.30 (3.05-5.92) 5.28 (3.96-6.69) 0.3402 
Metabolic syndrome, n (%) 6 (26.1) 2 (9.5) 0.3023 
BMC total, g 2241 (2034-2448) 2325 (2228-2616) 0.1145 
BMD, g/cm
2
 1.09 (1.05-1.11) 1.12 (1.07-1.16) 0.1068 
Values are expressed as medians (95%CI) unless otherwise specified. LPV/r = lopinavir ritonavir, EFV = efavirenz, BMI = body mass 
index, WHR = waist to hip ratio, HDL = high density lipoprotein, LDL = low density lipoprotein, VLDL = very low density lipoprotein, 
HOMA-IR = homeostasis model assessment method , BMC = bone mineral content, BMD = bone mineral density                               
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Table 3. Change in anthropometric and metabolic parameters over 48 weeks in patients treated with TDF/FTC plus LPV/r or EFV 
 LPV/r (n = 23) EFV (n =21)  
 
Baseline Week 48 
Within 
group P 
value 
Baseline Week 48 
Within 
group P 
value 
Between 
groups P 
value wk. 48 
Weight, kg 68.5 (60.0-74.9) 71.80 (66.0-77.0) 0.0537 69.0 (62.4-74.3) 74.1 (65.1-79.5) 0.0079 0.4884 
BMI, kg/m
2
 22.59 (20.37-24.65) 23.5 (22.04-25.22) 0.0653 22.78 (20.99-23.96) 24.85 (23.26-26.39) 0.0122 0.2678 
Waist circumference, cm 81.5 (77.0-87.0) 84.5 (81.0-92.0) 0.1066 81.5 (76.0-85.0) 86.5 (80.5-91.0) 0.1316 0.8491 
Systolic BP, mm Hg 110 (110-120) 120 (110-120) 0.2036 120 (110-127) 120 (120.128) 0.6836 0.3670 
Diastolic BP, mm Hg 70 (60-70) 70 (65-75) 0.6365 75 (70-80) 75 (70-80) 0.9005 0.1362 
Total cholesterol, mmol/l 4.04 (3.33-4.59) 5.22 (4.28-6.21) 0.0001 3.86 (3.69-4.56) 4.72 (4.20-5.22) 0.0011 0.1296 
HDL cholesterol, mmol/l 0.87 (0.79-1.29) 1.04 (0.90-1.35) 0.0089 1.02 (0.85-1.11) 1.14 (0.89-1.35) 0.0504 0.7338 
Total cholesterol/HDL ratio 4.33 (3.50-5.49) 4.81 (3.83-5.98) 0.5323 4.09 (3.46-4.61) 3.96 (3.31-5.05) 0.4344 0.2467 
LDL cholesterol, mmol/l 2.29 (1.82-2.67) 3.16 (2.46-3.97) 0.0025 2.42 (2.09-2.92) 2.70 (2.38-3.03) 0.0451 0.1778 
VLDL cholesterol, mmol/l 0.67 (0.40-0.88) 0.93 (0.67-1.13) 0.0226 0.54 (0.47-0.65) 0.60 (0.46-0.74) 0.4690 0.0110 
Triglycerides, mmol/l 1.45 (0.92-2.03) 2.14 (1.46-2.74) 0.0180 1.14 (1.01-1.40) 1.28 (1.01-1.59) 0.2360 0.0108 
Fasting glucose, mmol/l 4.80 (4.52-5.17) 5.00 (4.80-5.20) 0.2120 4.80 (4.60-5.05) 5.20 (5.07-5.42) 0.0031 0.0399 
Fasting insulin, pmol/l 28.0 (13.7-97.2) 7.15 (2.10-17.8) 0.2060 17.5 (13.0-35.0) 8.45 (2.60-15.35) 0.4175 0.8169 
HOMA-IR 1.77 (0.53-3.60) 0.55 (0.45-1.61) 0.8520 0.73 (0.65-1.40) 1.15 (0.51-1.95) 0.1230 0.4337 
All parameters expressed as median (interquartile range) unless otherwise specified. BMI = body mass index, BP = blood pressure, HDL = high density lipoprotein, LDL = low density 
lipoprotein, VLDL = very low density lipoprotein, mmol = milimoles, pmol = picomoles, HOMA = homeostasis model assessment method 
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Table 4. Change in fat parameters over 48 weeks in patients treated with TDF/FTC plus LPV/r or EFV 
 LPV/r (n = 23)  EFV (n = 21)   
Parameter Baseline Week 48 
Within 
group P 
value 
Baseline Week 48 
Within 
group P 
value 
Between 
groups P value 
(wk. 48) 
Whole body fat, g 12270 (9435-17392) 15152 (10428-22207) 0.0424 15743 (10417-17923) 16887 (13643-22605) 0.0370 0.6353 
Trunk fat, g 6052 (4429-8340) 7040 (5271-10863) 0.1225 6686 (4158-7698) 7187 (5161-12401) 0.1793 0.8744 
Left leg fat, g 1932 (1315-3234) 2628 (1614-3363) 0.0577 2814 (1771-3483) 3309 (2277-3718) 0.1680 0.2059 
Lower limb fat, g 3743 (2706-6425) 5298 (3216-6957) 0.0329 5591 (3537-6864) 6858 (4561-7451) 0.0937 0.2357 
Limb fat mass, g 5056 (3472-8152) 6884 (4133-9144) 0.0293 7077 (4584-8839) 8682 (5881-9478) 0.0809 0.2684 
Trunk/limb fat ratio 1.13 (0.99-1.26) 1.16 (0.99-1.32) 0.5486 1.05 (0.83-1.18) 0.97 (0.83-1.31) 0.6741 0.3230 
Fat mass ratio 1.49 (1.29-1.75) 1.51 (1.29-1.75) 0.5073 1.34 (1.07-1.59) 1.28 (1.05-1.73) 0.6352 0.2357 
% leg fat/BMI 0.79 (0.73-0.96) 1.03 (0.65-1.23) 0.2956 1.14 (0.85-1.31) 1.12 (0.93-1.37) 0.0630 0.1498 
Fat mass index, kg/m
2
 4.30 (3.05-5.92) 4.83 (3.55-7.34) 0.2439 5.28 (3.96-6.69) 5.51 (4.20-8.37) 0.0216 0.1701 
Metabolic syndrome, n (%) 6 (26.1) 8 (34.8) 0.7486 2 (9.5) 3 (14.3) 1.0 0.2225 
BMC total, g 2241 (2034-2448) 1781 (1670-1878) < 0.0001 2325 (2228-2616) 1924 (1783-1989) < 0.0001 0.0081 
BMD, g/cm
2
 1.09 (1.05-1.11) 1.05 (1.01-1.09) < 0.0001 1.12 (1.07-1.16) 1.12 (1.09-1.16) < 0.0001 0.0753 
All parameters expressed as median (interquartile range) unless otherwise specified. BMI = body mass index, BMC = bone mineral content, BMD = bone mineral density  
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Figure 1.  Relative abundance of mitochondrial DNA and cytochrome oxidase b transcript 
levels in abdominal SAT samples from patients exposed to LPV/r and EFV, both 
combined with TDF/FTC. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LPV/r = lopinavir/ritonavir, EFV = efavirenz, mtDNA = mitochondrial DNA, Cox II = cytochrome 
oxidase subunit II 
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Figure 2.  PPAR-γ and LPL transcript levels in abdominal SAT samples from patients exposed 
to LPV/r and EFV, both combined with TDF/FTC. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LPV/r = lopinavir/ritonavir, EFV = efavirenz, PPAR-γ = peroxisome proliferator-activated receptor gamma, LPL 
= lipoprotein lipase, CEBPa = CCAAT-enhancer binding protein-α, aP2/FABP4 = fatty acid bind protein-4,  
GLUT 4 = glucose transporter-4. 
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Figure 3.  TNF-α, IL-18, and MCP-1 transcript levels in abdominal SAT samples from patients 
exposed to LPV/r and EFV, both combined with TDF/FTC. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LPV/r = lopinavir/ritonavir, EFV = efavirenz, TNF-α = tumor necrosis factor alpha, MCP-1 = 
monocyte chemotactic protein 1, IL-18 = interleukin 18, GRP78 = 78 kDa glucose-regulated protein. 
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